FIBRILLYaTsIYa PREDSERDIY


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

全文:

受限制的访问

作者简介

- -

参考

  1. Клинические рекомендации. Фибрилляция и трепетание предсердий у взрослых. Общероссийская общественная организация «Российское кардиологическое общество», Всероссийское научное общество специалистов по клинической электрофизиологии, аритмологии и электростимуляции, Ассоциация сердечно-сосудистых хирургов России. 2020. Рубрикатор клинических рекомендаций Минздрава России. ID: 382. Доступ: https://cr.minzdrav.gov.ru/schema/382_1 (дата обращения - 01.11.2022).
  2. Wynn G.J., Todd D.M., Webber M. et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: Validation and improvement through a simple modification. Europace. 2014; 16(7): 965-72. https://dx.doi.org/10.1093/europace/eut395.
  3. Hindricks G., Potpara T., Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42(5): 373-498. https://dx.doi.org/10.1093/eurheartj/ehaa612.
  4. Lip G.Y., Frison L., Halperin J.L., Lane D.A.Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011; 57(2): 173-80. https://dx.doi.org/10.1016/joacc.2010.09.024.
  5. Olesen J.B., Lip G.Y., Hansen M.L. et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study. BMJ. 2011; 342: d124. https://dx.doi.org/10.1136/bmj.d124.
  6. Kirchhof P., Benussi S., Zamorano J.L. et al. Рекомендации ESC по лечению пациентов с фибрилляцией предсердий, разработанные совместно с EACTS. Российский кардиологический журнал. 2017; 22(7): 7-86. http://dx.doi.org/10.15829/1560-4071-2017-7-7-86. EDN: ZDEBUV.
  7. Zhang N., Guo J.H., Zhang H. et al.Comparison of intravenous ibutilide vs. propafenone for rapid termination of recent onset atrial fibrillation.Int J Clin Pract. 2005; 59(12): 1395-400. http://dx.doi.org/10.1111/j.1368-5031.2005.00705.x.
  8. Martinez-Marcos F.J., Garcia-Garmendia J.L., Ortega-Carpio A. et al.Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol. 2000; 86(9): 950-53. http://dx.doi.org/10.1016/s0002-9149(00)01128-0.
  9. Alboni P., Botto G.L., Baldi N. et al. Outpatient treatment of recent-onset atrial fibrillation with the «pill-in-the-pocket» approach. N Engl J Med. 2004; 351(23): 2384-91. http://dx.doi.org/10.1056/NEJMoa041233.
  10. Khan I.A. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol. 2001; 37(2): 542-47. http://dx.doi.org/10.1016/s0735-1097(00)01116-5.
  11. Saborido C.M., Hockenhull J., Bagust A. et al. Systematic review and cost-effectiveness evaluation of «pill-in-the-pocket» strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy. Health Technol Assess. 2010; 14(31): iii-iv, 1-75. http://dx.doi.org/10.3310/hta14310.
  12. В.Л. Дощицин, А.В. Сыров. Применение пропафенона и соталола при лечении фибрилляции предсердий. Терапия. 2022; 8(8): 124-136.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Bionika Media, 2022